MYCN and neuroblastoma: By contrast, considering the two subgroups of low-risk neuroblastoma, that is, non-MYCN-amplified stage 1, 2 and 3 patients and non-MYCN-amplified stage 4 of infant <18 months, expression levels of both miR-487b and miR-410 displayed a highly significant association with overall and disease-free survival.